The Role of Reactive Oxygen Species and the Microbiome in Toxicant Induced Liver Fibrosis

Research Project 4


Project Narative

Obesity and non-alcoholic fatty liver (NAFL) are prevalent in many impoverished communities, contributes to health disparities, and increases the risk in these individuals developing toxicant-associated steatohepatitis (TASH) if exposed to environmental toxicants such as those found at NPL-Superfund sites. Since Hispanic and Native Americans are genetically predisposed to develop NAFL as a result of polymorphisms in the PNPLA3 gene, we propose to investigate the contribution of reactive oxygen species towards promoting TASH when the PNPLA3 gene with human polymorphic alleles are combined in mice expressing the inducible human CYP2E1 gene. The contribution of intestinal microbiota on increased susceptibility of toxicants generating TASH will be pursued, and the mechanisms of these responses will be examined in “human livers in the dish” (exVive3D™ Liver) following exposure to Superfund toxicants to examine if this novel culture system can be exploited to investigate TASH.

Summary of Project

Environmental exposures to industrial chemicals, such as carbon tetrachloride (CCl4) causes toxicant-induced steatohepatitis (TASH) characterized by fatty liver, inflammation, and fibrosis. Although susceptibility to occupational and environmental TASH may be modified by genetic predisposition (SNPs) and nutritional factors, our central hypothesis are that obesity and non-alcoholic fatty liver (NAFL) increase the severity of TASH by (1) Inducing the activity of cytochrome P450 2E1, (2) Increasing the generation of reactive oxygen species (ROS) by activating NADPH oxidases (NOXs), and (3) Inducing dysbiosis of the gut microbiome and increased intestinal permeability. The goal is to determine the mechanism by which obesity and CCl4 synergistically facilitate progression of TASH to liver cirrhosis, and develop new approaches to identifying toxicants that induce TASH. The following specific aims have been developed: (AIM1) To study the effect of “fast food diet” (FFD)-induced obesity and NAFL on CCl4-induced TASH. We propose to use improved diet-induced and genetic mouse models, including mice expressing human CYP2E1 gene and knock-in PNPLA3 mice (expressing the human SNP associated with NAFL). Since hCYP2E1 mice are more susceptible to toxicants, we anticipate that production of Nox1 and Nox4, release of pro-inflammatory cytokines by activated Kupffer cells, and development of liver fibrosis will closely recapitulate the pathology observed in patients with NASH/TASH. The specific role of NOX 1 and 4 in this TASH model will be assessed by pharmacological inhibition. (AIM2) To investigate the role of dysbiosis in transgenic mice subjected to fecal microbiota transplantation (FMT) from patients with NASH or matched normal controls from a well phenotyped cohort. We propose that the microbiome from NASH patients will render mice more sensitive to CCl4, while the transfer of “healthy” microbiota will decrease liver fibrosis in these mice. We will then do a therapeutic intervention by FMT of normal flora into a mouse with liver fibrosis to assess reversal of TASH. (AIM3) To translate our findings in mice to humans, we will utilize a “human liver in a dish” (exVive3D™ Livers, Organovo), a 3D culture composed of 4 primary hepatic cell types that maintains architectural and functional features of the human liver for greater than 40 days. These cultures will be subjected to Superfund toxicants and then assessed for TASH. The effects of potential drugs, such as Nox inhibitors, will be assessed in these 3D culture models of TASH. Overall, we will develop a high through-put system for ex vivo drug screening by measuring hepatotoxicity of Superfund toxicants and effectiveness of therapeutic interventions.

Publications

PubMed Central ID: 

Haas ME, Pirruccello JP, Friedman SN, Wang M, Emdin CA, Ajmera VH, Simon TG, Homburger JR, Guo X, Budoff M, Corey KE, Zhou AY, Philippakis A, Ellinor PT, Loomba R, Batra P, Khera AV. Machine learning enables new insights into genetic contributions to liver fat accumulation. Cell Genom. 2021 Dec 8;1(3):100066. doi:10.1016/j.xgen.2021.100066. PMID: 34957434; PMCID: PMC8699145.

PubMedID: 34957434

Danis N, Weeks SR, Kim A, Baghdadi A, Ghadimi M, Kamel IR, Saberi B, Woreta T, Garonzik-Wang J, Philosophe B, Gurakar A, Loomba R. Noninvasive Risk Stratification for Nonalcoholic Fatty Liver Disease Among Living Liver Donor Candidates: A Proposed Algorithm. Liver Transpl. 2021 Nov 9. doi:10.1002/lt.26365. Epub ahead of print. PMID: 34753223.

PubMedID: 34753223

Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Tada T, Nakamura S, Yasuda S, Toyoda H, Loomba R, Izumi N. Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. Hepatol Commun. 2022 Mar;6(3):461-472. doi: 10.1002/hep4.1833. Epub 2021 Oct 22. PMID: 34676692.

PubMedID: 34676692
PubMed Central ID: 

Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, Abdelmalek MF, Harrison SA, Loomba R, Mantzoros CS, Bugianesi E, Eckel RH, Kaplan LM, El-Serag HB, Cusi K. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2021 Nov;161(5):1657-1669. doi:10.1053/j.gastro.2021.07.049. Epub 2021 Sep 20. PMID: 34602251; PMCID: PMC8819923.

PubMedID: 34602251

Tamaki N, Imajo K, Sharpton S, Jung J, Kawamura N, Yoneda M, Valasek MA, Behling C, Sirlin CB, Nakajima A, Loomba R. Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis. Hepatology. 2022 Mar;75(3):661-672. doi:10.1002/hep.32145. Epub 2021 Dec 15. PMID: 34496054.

PubMedID: 34496054
PubMed Central ID: 

Majzoub AM, Nayfeh T, Barnard A, Munaganuru N, Dave S, Singh S, Murad MH, Loomba R. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Aliment Pharmacol Ther. 2021 Oct;54(7):880-889. doi:10.1111/apt.16583. Epub 2021 Aug 25. PMID: 34435378;PMCID: PMC8711247.

 

PubMedID: 34435378
PubMed Central ID: 

Tamaki N, Higuchi M, Kurosaki M, Loomba R, Izumi N; MRCH Liver Study Group. Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2021 Jul 16:S1542-3565(21)00752-7. doi:10.1016/j.cgh.2021.07.021. Epub ahead of print. PMID: 34280550; PMCID: PMC8761224.

PubMedID: 34280550
PubMed Central ID: 

Vilarinho S, Ajmera V, Zheng M, Loomba R. Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD. Hepatology. 2021 Oct;74(4):2241-2250. doi:10.1002/hep.32047. PMID: 34233030;PMCID: PMC8463418.

PubMedID: 34233030

Park JG, Jung J, Loomba R. Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non-alcoholic fatty liver disease-a realm for non-invasive testing. Authors' reply. Aliment Pharmacol Ther. 2021 Jul;54(2):216. doi: 10.1111/apt.16462. PMID: 34170539.

PubMedID: 34170539
PubMed Central ID: 

Jiao N, Loomba R, Yang ZH, Wu D, Fang S, Bettencourt R, Lan P, Zhu R, Zhu L. Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD. Physiol Genomics. 2021 Aug 1;53(8):336-348. doi:10.1152/physiolgenomics.00011.2021. Epub 2021 Jun 21. PMID: 34151600; PMCID: PMC8424563.

PubMedID: 34151600

Ajmera V, Liu A, Bettencourt R, Dhar D, Richards L, Loomba R. The impact of genetic risk on liver fibrosis in non-alcoholic fatty liver disease as assessed by magnetic resonance elastography. Aliment Pharmacol Ther. 2021 Jul;54(1):68-77. doi:10.1111/apt.16392. Epub 2021 May 11. PMID: 33975381.

PubMedID: 33975381
PubMed Central ID: 

Tamaki N, Munaganuru N, Jung J, Yonan AQ, Loomba RR, Bettencourt R, Ajmera V, Valasek MA, Behling C, Sirlin CB, Loomba R. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. Gut. 2021 Apr 21:gutjnl-2021-324264. doi:10.1136/gutjnl-2021-324264. Epub ahead of print. PMID: 33883248; PMCID: PMC8594562.

PubMedID: 33883248
PubMed Central ID: 

Park JG, Jung J, Verma KK, Kang MK, Madamba E, Lopez S, Qas Yonan A, Liu A, Bettencourt R, Sirlin C, Loomba R. Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2021 May;53(9):1030-1037. doi:10.1111/apt.16324. Epub 2021 Mar 25. PMID: 33764550; PMCID: PMC8514119.

 

PubMedID: 33764550

Byra M, Han A, Boehringer AS, Zhang YN, O'Brien WD Jr, Erdman JW Jr, Loomba R, Sirlin CB, Andre M. Liver Fat Assessment in Multiview Sonography Using Transfer Learning With Convolutional Neural Networks. J Ultrasound Med. 2022 Jan;41(1):175-184. doi:10.1002/jum.15693. Epub 2021 Mar 10. PMID: 33749862.

PubMedID: 33749862
PubMed Central ID: 

Caussy C, Aubin A, Loomba R. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Curr Diab Rep. 2021 Mar 19;21(5):15. doi:10.1007/s11892-021-01383-7. PMID: 33742318; PMCID: PMC8805985.

PubMedID: 33742318
PubMed Central ID: 

Ruuskanen MO, Åberg F, Männistö V, Havulinna AS, Méric G, Liu Y, Loomba R, Vázquez-Baeza Y, Tripathi A, Valsta LM, Inouye M, Jousilahti P, Salomaa V, Jain M, Knight R, Lahti L, Niiranen TJ. Links between gut microbiome composition and fatty liver disease in a large population sample. Gut Microbes. 2021 Jan-Dec;13(1):1-22. doi:10.1080/19490976.2021.1888673. PMID: 33651661; PMCID: PMC7928040.

PubMedID: 33651661
PubMed Central ID: 

Ajmera V, Thompson WK, Smith DM, Malhotra A, Mehta RL, Tolia V, Yin J, Sriram K, Insel PA, Collier S, Richards L, Loomba R. RAMIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19. Contemp Clin Trials. 2021 Apr;103:106330. doi:10.1016/j.cct.2021.106330. Epub 2021 Feb 22. PMID: 33631357; PMCID: PMC7899027.

 

PubMedID: 33631357
PubMed Central ID: 

Rosenthal SB, Liu X, Ganguly S, Dhar D, Pasillas MP, Ricciardelli E, Li RZ, Troutman TD, Kisseleva T, Glass CK, Brenner DA. Heterogeneity of HSCs in a Mouse Model of NASH. Hepatology. 2021 Aug;74(2):667-685. doi:10.1002/hep.31743. Epub 2021 Aug 10. PMID: 33550587; PMCID: PMC8346581.

PubMedID: 33550587

Dhar D, Loomba R. Emerging Metabolic and Transcriptomic Signature of PNPLA3-Associated NASH. Hepatology. 2021 Apr;73(4):1248-1250. doi:10.1002/hep.31735. PMID: 33544416.

PubMedID: 33544416
PubMed Central ID: 

Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Loomba R, Izumi N. Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus. Clin Infect Dis. 2021 Nov 2;73(9):e3349-e3354. doi:10.1093/cid/ciaa1307. PMID: 33544129; PMCID: PMC8824825.

PubMedID: 33544129
PubMed Central ID: 

Hagström H, Adams LA, Allen AM, Byrne CD, Chang Y, Grønbaek H, Ismail M, Jepsen P, Kanwal F, Kramer J, Lazarus JV, Long MT, Loomba R, Newsome PN, Rowe IA, Ryu S, Schattenberg JM, Serper M, Sheron N, Simon TG, Tapper EB, Wild S, Wong VW, Yilmaz Y, Zelber-Sagi S, Åberg F. Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement. Hepatology. 2021 Jul;74(1):474-482. doi: 10.1002/hep.31726. Epub 2021 Jun 22. PMID: 33486773; PMCID: PMC8515502.

PubMedID: 33486773
PubMed Central ID: 

Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab. 2021 May;23(5):1069-1083. doi: 10.1111/dom.14322. Epub 2021 Feb 10. PMID: 33464677; PMCID: PMC8248154.

 

PubMedID: 33464677
PubMed Central ID: 

Ajmera V, Loomba R. Imaging biomarkers of NAFLD, NASH, and fibrosis. Mol Metab. 2021 Aug;50:101167. doi:10.1016/j.molmet.2021.101167. Epub 2021 Jan 15. PMID: 33460786; PMCID: PMC8324681.

PubMedID: 33460786
PubMed Central ID: 

Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):223-238. doi:10.1038/s41575-020-00381-6. Epub 2020 Dec 21. PMID: 33349658; PMCID: PMC8016738.

PubMedID: 33349658
PubMed Central ID: 

Sharpton SR, Schnabl B, Knight R, Loomba R. Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease. Cell Metab. 2021 Jan 5;33(1):21-32. doi:10.1016/j.cmet.2020.11.010. Epub 2020 Dec 8. PMID: 33296678; PMCID: PMC8414992.

PubMedID: 33296678
PubMed Central ID: 

Jung J, Loomba RR, Imajo K, Madamba E, Gandhi S, Bettencourt R, Singh S, Hernandez C, Valasek MA, Behling C, Richards L, Fowler K, Sirlin CB, Nakajima A, Loomba R. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut. 2021 Oct;70(10):1946-1953. doi: 10.1136/gutjnl-2020-322976. Epub 2020 Nov 19. PMID: 33214165; PMCID: PMC8131405.

PubMedID: 33214165
PubMed Central ID: 
Sriram, K., Loomba, R., & Insel, P. A. (2020). Targeting the renin-angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenges. Proceedings of the National Academy of Sciences of the United States of America, 117(47), 29274–29282. https://doi.org/10.1073/pnas.2009875117
PubMedID: 33203679
PubMed Central ID: 

Loomba R. MRI-Proton Density Fat Fraction Treatment Response Criteria in Nonalcoholic Steatohepatitis. Hepatology. 2021 Mar;73(3):881-883. doi:10.1002/hep.31624. PMID: 33179266; PMCID: PMC8221026.

PubMedID: 33179266
PubMed Central ID: 
Oh, T. G., Kim, S. M., Caussy, C., Fu, T., Guo, J., Bassirian, S., Singh, S., Madamba, E. V., Bettencourt, R., Richards, L., Yu, R. T., Atkins, A. R., Huan, T., Brenner, D. A., Sirlin, C. B., Downes, M., Evans, R. M., & Loomba, R. (2020). A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis. Cell metabolism, 32(5), 901. https://doi.org/10.1016/j.cmet.2020.10.015
PubMedID: 33147487
PubMed Central ID: 

Long MT, Zhang X, Xu H, Liu CT, Corey KE, Chung RT, Loomba R, Benjamin EJ. Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study. Hepatology. 2021 Feb;73(2):548-559. doi:10.1002/hep.31608. Epub 2021 Feb 6. PMID: 33125745; PMCID: PMC8515503.

PubMedID: 33125745
PubMed Central ID: 

Ajmera VH, Cachay ER, Ramers CB, Bassirian S, Singh S, Bettencourt R, Richards L, Hamilton G, Middleton M, Fowler K, Sirlin C, Loomba R. Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard. Clin Infect Dis. 2021 Jun 15;72(12):2124-2131. doi:10.1093/cid/ciaa429. PMID: 32975278; PMCID: PMC8204791.

PubMedID: 32975278
PubMed Central ID: 

Stine JG, Munaganuru N, Barnard A, Wang JL, Kaulback K, Argo CK, Singh S, Fowler KJ, Sirlin CB, Loomba R. Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2021 Nov;19(11):2274-2283.e5. doi:10.1016/j.cgh.2020.08.061. Epub 2020 Aug 31. PMID: 32882428; PMCID: PMC7914285.

PubMedID: 32882428
PubMed Central ID: 
Todoric, J., Di Caro, G., Reibe, S., Henstridge, D. C., Green, C. R., Vrbanac, A., Ceteci, F., Conche, C., McNulty, R., Shalapour, S., Taniguchi, K., Meikle, P. J., Watrous, J. D., Moranchel, R., Najhawan, M., Jain, M., Liu, X., Kisseleva, T., Diaz-Meco, M. T., Moscat, J., … Karin, M. (2020). Fructose stimulated de novo lipogenesis is promoted by inflammation. Nature metabolism, 2(10), 1034–1045. https://doi.org/10.1038/s42255-020-0261-2
PubMedID: 32839596
PubMed Central ID: 

Loomba R, Ling L, Dinh DM, DePaoli AM, Lieu HD, Harrison SA, Sanyal AJ. The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH. Hepatology. 2021 Jan;73(1):126-143. doi:10.1002/hep.31523. Epub 2020 Dec 11. PMID: 32794259; PMCID: PMC7898628.

PubMedID: 32794259
PubMed Central ID: 
Verna, E. C., Serper, M., Chu, J., Corey, K., Fix, O. K., Hoyt, K., Page, K. A., Loomba, R., Li, M., Everson, G. T., Fried, M. W., Garcia-Tsao, G., Terrault, N., Lok, A. S., Chung, R. T., & Reddy, K. R. (2020). Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. Hepatology (Baltimore, Md.), 72(5), 1819–1837. https://doi.org/10.1002/hep.31491
PubMedID: 32740969
PubMed Central ID: 
Hydes, T. J., Ravi, S., Loomba, R., & E Gray, M. (2020). Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH. Clinical and molecular hepatology, 26(4), 383–400. https://doi.org/10.3350/cmh.2020.0067
PubMedID: 32674529
PubMed Central ID: 
Oh, T. G., Kim, S. M., Caussy, C., Fu, T., Guo, J., Bassirian, S., Singh, S., Madamba, E. V., Bettencourt, R., Richards, L., Yu, R. T., Atkins, A. R., Huan, T., Brenner, D. A., Sirlin, C. B., Downes, M., Evans, R. M., & Loomba, R. (2020). A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis. Cell metabolism, 32(5), 878–888.e6. https://doi.org/10.1016/j.cmet.2020.06.005
PubMedID: 32610095
PubMed Central ID: 
Long, M. T., Gandhi, S., & Loomba, R. (2020). Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease. Metabolism: clinical and experimental, 111S, 154259. https://doi.org/10.1016/j.metabol.2020.154259
PubMedID: 32387227
PubMed Central ID: 
Dufour, J. F., Caussy, C., & Loomba, R. (2020). Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut, 69(10), 1877–1884. https://doi.org/10.1136/gutjnl-2019-319104
PubMedID: 32381514
PubMed Central ID: 
Han, A., Byra, M., Heba, E., Andre, M. P., Erdman, J. W., Jr, Loomba, R., Sirlin, C. B., & O'Brien, W. D., Jr (2020). Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat with Radiofrequency Ultrasound Data Using One-dimensional Convolutional Neural Networks. Radiology, 295(2), 342–350. https://doi.org/10.1148/radiol.2020191160
PubMedID: 32096706
PubMed Central ID: 
Xu J, Ma HY, Liu X, Rosenthal S, Baglieri J, McCubbin R, Sun M, Koyama Y, Geoffroy CG, Saijo K, Shang L, Nishio T, Maricic I, Kreifeldt M, Kusumanchi P, Roberts A, Zheng B, Kumar V, Zengler K, Pizzo DP, Hosseini M, Contet C, Glass CK, Liangpunsakul S, Tsukamoto H, Gao B, Karin M, Brenner DA, Koob GF, Kisseleva T. Blockade of IL-17 signaling reverses alcohol-induced liver injury and excessive alcohol drinking in mice. JCI Insight. 2020 Feb 13;5(3):e131277. doi: 10.1172/jci.insight.131277.
PubMedID: 32051339

Zhao P, Sun X, Chaggan C, Liao Z, In Wong K, He F, Singh S, Loomba, R, Karin M, Witztum JL, Saltiel AR. (2020) An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis. Science. Feb 7; 367(6478):652-660.
doi: 10.1126/science.aay0542

PubMedID: 32029622
PubMed Central ID: 
Han, A., Zhang, Y. N., Boehringer, A. S., Montes, V., Andre, M. P., Erdman, J. W., Jr, Loomba, R., Valasek, M. A., Sirlin, C. B., & O'Brien, W. D., Jr (2020). Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease by Using Quantitative US. Radiology, 295(1), 106–113. https://doi.org/10.1148/radiol.2020191152
PubMedID: 32013792
PubMed Central ID: 
Loomba, R., Lim, J. K., Patton, H., & El-Serag, H. B. (2020). AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology, 158(6), 1822–1830. https://doi.org/10.1053/j.gastro.2019.12.053
PubMedID: 32006545
PubMed Central ID: 
Stender, S., & Loomba, R. (2020). PNPLA3 Genotype and Risk of Liver and All-Cause Mortality. Hepatology (Baltimore, Md.), 71(3), 777–779. https://doi.org/10.1002/hep.31113
PubMedID: 31954067
PubMed Central ID: 

Dhar, D., Baglieri, J., Kisseleva, T. and Brenner, D.A. (2020) Mechanisms of liver fibrosis and its role in cancer. Exp Biol Med (Maywood). Jan 10:1535370219898141. doi: 10.1177/1535370219898141

PubMedID: 31924111
PubMed Central ID: 

Ma HY, Yamamoto G, Xu J, Liu X, Karin D, Kim JY, Alexandrov LB, Koyama Y, Nishio T, Benner C, Heinz S, Rosenthal SB, Liang S, Sun M, Karin G, Zhao P, Brodt P, Mckillop IH, Quehenberger O, Dennis E, Saltiel A, Tsukamoto H, Gao B, Karin M, Brenner DA, Kisseleva T. (2019) IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease. J Hepatol. Dec 31.
doi: 10.1016/j.jhep.2019.12.016

PubMedID: 31899206
PubMed Central ID: 
Balakrishnan, M., & Loomba, R. (2020). The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD. Journal of clinical gastroenterology, 54(2), 107–113. https://doi.org/10.1097/MCG.0000000000001284
PubMedID: 31789757
PubMed Central ID: 

Sun, X., Seidman, J.S., Zhao, P., Troutman, T.D., Spann, N.J., Que, X., Zhou, F., Liao, Z., Pasillas, M., Yang, X., Magida, J.A., Kisseleva, T., Brenner, D.A.,Downes, M., Evans, R.M., Saltiel, A.R., Tsimikas, S., Glass, C.K., Witztum, J.L. (2020) Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis. Cell Metab. Jan 7;31(1):189-206.e8.
doi: 10.1016/j.cmet.2019.10.014

PubMedID: 31761566
PubMed Central ID: 

Loomba, R., Adams, L.A. (2019) The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH. Hepatology. Dec;70(6):1885-1888.  doi: 10.1002/hep.30946

PubMedID: 31520407
PubMed Central ID: 

Pai, R.K., Kleiner, D.E., Hart, J., Adeyi, O.A., Clouston, A.D., Behling, C.A., Jain, D., Kakar, S., Brahmania, M., Burgart, L., Batts, K.P., Valasek, M.A., Torbenson, M.S., Guindi, M., Wang, H.L., Ajmera, V., Adams, L.A., Parker, C.E., Feagan, B.G., Loomba, R., Jairath, V. (2019) Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. Aliment Pharmacol Ther. 50(10):1100-1111. doi: 10.1111/apt.15503. (https://onlinelibrary.wiley.com/doi/full/10.1111/apt.15503) Epub 2019 Oct 3.

PubMedID: 31583739
PubMed Central ID: 

Ajmera VH, Liu A, Singh S, Yachoa G, Ramey M, Bhargava M, Zamani A, Lopez S, Mangla N, Bettencourt R, Rizo E, Valasek M, Behling C, Richards L, Sirlin C, Loomba R. (2019) Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in NAFLD. Hepatology. Sep 25. doi: 10.1002/hep.30974


PubMedID: 31556124
PubMed Central ID: 

Wang, L., Mazagova, M., Pan, C., Yang, S., Brandl, K., Liu, J., Reilly, S.M., Wang, Y., Miao, Z., Loomba, R., Lu, N., Guo, Q., Liu, J., Yu, R.T., Downes, M., Evans, R.M., Brenner, D.A., Saltiel, A.R., Beutler, B., Schnabl, B. (2019) YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity. Proc Natl Acad Sci U S A. 116(30):15184-15193. doi: 10.1073/pnas.1904360116. (https://www.pnas.org/content/116/30/15184) Epub 2019 Jul 9.

PubMedID: 31289229
PubMed Central ID: 

Mouzaki, M., Loomba, R. (2019) Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention. Therap Adv Gastroenterol. 12:1756284819858470. doi: 10.1177/1756284819858470. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591661/) eCollection 2019. Review.

PubMedID: 31258623
PubMed Central ID: 

Mangla, N., Ajmera, V.H., Caussy, C., Sirlin, C., Brouha, S., Bajwa-Dulai, S., Madamba, E., Bettencourt, R., Richards, L., Loomba, R. (2019) Liver Stiffness Severity is Associated With Increased Cardiovascular Risk in Patients With Type 2 Diabetes. Clinical gastroenterology and hepatology. May 14. doi: 10.1016/j.cgh.2019.05.003

PubMedID: 31100460
PubMed Central ID: 

Baglieri J, Brenner DA, Kisseleva T. (2019) The Role of Fibrosis and Liver-Associated Fibroblasts in the Pathogenesis of Hepatocellular Carcinoma. Int J Mol Sci. Apr 7; 20(7). pii: E1723. Review.  doi: 10.3390/ijms20071723

PubMedID: 30959975
PubMed Central ID: 

Mills, P.J., Caussy, C., Loomba, R. (2019) Glyphosate Excretion is Associated With Steatohepatitis and Advanced Liver Fibrosis in Patients With Fatty Liver Disease. Clin Gastroenterol Hepatol. pii: S1542-3565(19)30361-1. doi: 10.1016/j.cgh.2019.03.045. (https://www.sciencedirect.com/science/article/abs/pii/S1542356519303611?...) [Epub ahead of print]

PubMedID: 30954713
PubMed Central ID: 

Caussy, C., Tripathi, A., Humphrey, G., Bassirian, S., Singh, S., Faulkner, C., Bettencourt, R., Rizo, E., Richards, L., Xu, Z.Z., Downes, M.R., Evans, R.M., Brenner, D.A., Sirlin, C.B., Knight, R., Loomba, R. (2019) A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nat Commun. Mar 29; 10(1):1406. doi: 10.1038/s41467-019-09455-9

PubMedID: 30926798

Caussy, C., Bhargava, M., Villesen, I.F., Gudmann, N.S., Leeming, D.J., Karsdal, M.A., Faulkner, C., Bao, D., Liu ,A., Lo, M.T., Bettencourt, R., Bassirian, S., Richards, L., Brenner, D.A., Chen, C.H., Sirlin, C.B., Loomba, R. (2019) Collagen Formation Assessed by N-Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography. Hepatology. 70(1):127-141. doi: 10.1002/hep.30610. (https://doi.org/10.1002/hep.30610) Epub 2019 Apr 29.

PubMedID: 30859582

Castera, L., Friedrich-Rust, M., Loomba, R. (2019) Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 156(5):1264-1281.e4. doi: 10.1053/j.gastro.2018.12.036. Epub 2019 Jan 18. Review.

PubMedID: 30660725
PubMed Central ID: 

Liang, S., Ma, H.Y., Zhong, Z., Dhar, D., Liu, X., Xu, J., Koyama, Y., Nishio, T., Karin, D., Karin, G., Mccubbin, R., Zhang, C., Hu, R., Yang, G., Chen, L., Ganguly, S., Lan, T., Karin, M., Kisseleva, T., Brenner, D.A. (2018) NADPH Oxidase 1 in Liver Macrophages Promotes Inflammation and Tumor Development in Mice. Gastroenterology. 156(4):1156-1172.e6. doi: 10.1053/j.gastro.2018.11.019. Epub 2018 Nov 13.

PubMedID: 30445007

Kim, J.Y., Garcia-Carbonell, R., Yamachika, S., Zhao, P., Dhar, D., Loomba, R., Kaufman, R.J., Saltiel, A.R., Karin, M. (2018) ER Stress Drives Lipogenesis and Steatohepatitis via Caspase-2 Activation of S1P. Cell. 175(1):133-145.e15. doi: 10.1016/j.cell.2018.08.020. Epub 2018 Sep 13.

PubMedID: 30220454
PubMed Central ID: 

Zhong, Z., Liang, S., Sanchez-Lopez, E., He, F., Shalapour, S., Lin, X.J., Wong, J., Ding, S., Seki, E., Schnabl, B., Hevener, A.L., Greenberg, H.B., Kisseleva, T., Karin, M. (2018) New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature. 560(7717):198-203. doi: 10.1038/s41586-018-0372-z. Epub 2018 Jul 25.

PubMedID: 30046112
PubMed Central ID: 

Brenner, D.A. (2018) Of Mice and Men and Nonalcoholic Steatohepatits. Hepatology. 68(6):2059-2061. doi: 10.1002/hep.30186. Epub 2018 Nov 13. No abstract available.

PubMedID: 30033687

Tripathi, A., Debelius, J., Brenner, D.A., Karin, M., Loomba, R., Schnabl, B., Knight, R. (2018) The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 15(12):785. doi: 10.1038/s41575-018-0031-8.

PubMedID: 29785003
PubMed Central ID: 

Ajmera, V., Park, C.C., Caussy, C., Singh, S., Hernandez, C., Bettencourt, R., Hooker, J., Sy, E., Behling, C., Xu, R., Middleton, M.S., Valasek, M.A., Faulkner, C., Rizo, E., Richards, L., Sirlin, C.B., Loomba, R. (2018) Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 155(2):307-310.e2. doi: 10.1053/j.gastro.2018.04.014. Epub 2018 Apr 13.

PubMedID: 29660324

Caussy, C., Hsu, C., Lo, M.T., Liu, A., Bettencourt, R., Ajmera, V.H., Bassirian, S., Hooker, J., Sy, E., Richards, L., Schork, N., Schnabl, B., Brenner, D.A., Sirlin, C.B., Chen, C.H., Loomba, R.; Genetics of NAFLD in Twins Consortium. (2018) Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology. doi: 10.1002/hep.29892.

PubMedID: 29572891
PubMed Central ID: 

Desai, A.P., Mohan, P., Roubal, A.M., Bettencourt, R., Loomba, R. (2018) Geographic Variability in Liver Disease-Related Mortality Rates in the United States. Am J Med. 131(7):728-734. doi: 10.1016/j.amjmed.2018.01.047. Epub 2018 Feb 26.

PubMedID: 29496501
PubMed Central ID: 

Xu J., Ma H.Y., Liang S., Sun M., Karin G., Koyama Y., Hu R., Quehenberger O., Davidson N.O., Dennis E.A., Kisseleva T., Brenner D.A. (2017) The role of human cytochrome P450 2E1 in liver inflammation and fibrosis. Hepatol Commun. 1(10):1043-1057. doi: 10.1002/hep4.1115. eCollection 2017 Dec.

PubMedID: 29404441

Hartmann P., Hochrath K., Horvath A., Chen P., Seebauer C.T., Llorente C., Wang L., Alnouti Y., Fouts D.E., Stärkel P., Loomba R., Coulter S., Liddle C., Yu R.T., Ling L., Rossi S.J., DePaoli A.M., Downes M., Evans R.M., Brenner D.A., Schnabl B. (2017) Modulation of the intestinal bile acid-FXR-FGF15 axis improves alcoholic liver disease in mice. Hepatology. doi: 10.1002/hep.29676.

PubMedID: 29159825
PubMed Central ID: 

Shalapour, S., Lin, X.J., Bastian, I.N., Brain, J., Burt, A.D., Aksenov, A.A., Vrbanac, A.F., Li, W., Perkins, A., Matsutani, T., Zhong, Z., Dhar, D., Navas-Molina, J.A., Xu, J., Loomba, R., Downes, M., Yu, R.T., Evans, R.M., Dorrestein, P.C., Knight, R., Benner, C., Anstee, Q.M., Karin, M. (2017). Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature. 551, 340-345. doi: 10.1038/nature24302.

PubMedID: 29144460
PubMed Central ID: 

Tapper, E.B., Loomba, R. (2018) Nonalcoholic fatty liver disease, metabolic syndrome, and the fight that will define clinical practice for a generation of hepatologists. Hepatology. 67(5):1657-1659. doi: 10.1002/hep.29722. Epub 2018 Apr 1.

PubMedID: 29222913

Brouha, S.S., Nguyen, P., Bettencourt, R., Sirlin, C.B., Loomba, R. (2018) Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: A prospective study. Eur Radiol. 28(4):1345-1355. doi: 10.1007/s00330-017-5075-6. Epub 2017 Oct 20.

PubMedID: 29058029
PubMed Central ID: 

Song IJ, Yang YM, Inokuchi-Shimizu S, Roh YS, Yang L, Seki E. (2018) The contribution of toll-like receptor signaling to the development of liver fibrosis and cancer in hepatocyte-specific TAK1-deleted mice. Int J Cancer. 142(1):81-91. doi: 10.1002/ijc.31029. Epub 2017 Sep 23.

PubMedID: 28875549
PubMed Central ID: 

Caussy C., Soni M., Cui J., Bettencourt R., Schork N., Chen C.H., Ikhwan M.A., Bassirian S., Cepin S., Gonzalez M.P., Mendler M., Kono Y., Vodkin I., Mekeel K., Haldorson J., Hemming A., Andrews B., Salotti J., Richards L., Brenner D.A., Sirlin C.B., Loomba R., Familial NAFLD Cirrhosis Research Consortium. (2017) Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. J Clin Invest. 127(7):2697-2704. doi: 10.1172/JCI93465. Epub 2017 Jun 19.

PubMedID: 28628033
PubMed Central ID: 

Vollmann E.H., Cao L., Amatucci A., Reynolds T., Hamann S., Dalkilic-Liddle I., Cameron T.O., Hossbach M., Kauffman K.J., Mir F.F., Anderson D.G., Novobrantseva T., Koteliansky V., Kisseleva T., Brenner D., Duffield J., Burkly L.C. (2017) Identification of Novel Fibrosis Modifiers by In Vivo siRNA Silencing. Mol Ther Nucleic Acids. 7:314-323. doi: 10.1016/j.omtn.2017.04.014. Epub 2017 Apr 20.

PubMedID: 28624207
PubMed Central ID: 

Reinders M.E., Wardi G., Bettencourt R., Bouland D., Bazick J., Mendler M., Vodkin I., Kalmaz D., Savides T., Brenner D., Sell R.E., Loomba R. (2017) Increased Risk of Death, in the Hospital and Outside the Intensive Care Unit, for Patients With Cirrhosis After Cardiac Arrest. Clin Gastroenterol Hepatol. 15(11):1808-1810. doi: 10.1016/j.cgh.2017.05.044. Epub 2017 Jun 7.

PubMedID: 28602970
PubMed Central ID: 

Kim R.G., Loomba R., Prokop L.J., Singh S. (2017) Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 15(10):1521-1530.e8. doi: 10.1016/j.cgh.2017.04.039. Epub 2017 May 4.

PubMedID: 28479502
PubMed Central ID: 

Loomba R., Seguritan V., Li W., Long T., Klitgord N., Bhatt A., Dulai P.S., Caussy C., Bettencourt R., Highlander S.K., Jones M.B., Sirlin C.B., Schnabl B., Brinkac L., Schork N., Chen C.H., Brenner D.A., Biggs W., Yooseph S., Venter J.C., Nelson K.E. (2017) Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 25(5):1054-1062.e5. doi: 10.1016/j.cmet.2017.04.001.

PubMedID: 28467925
PubMed Central ID: 

Koyama Y., Wang P., Liang S., Iwaisako K., Liu X., Xu J., Zhang M., Sun M., Cong M., Karin D., Taura K., Benner C., Heinz S., Bera T., Brenner D.A., Kisseleva T. (2017) Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis. J Clin Invest. 127(4):1254-1270. doi: 10.1172/JCI88845. Epub 2017 Mar 13.

PubMedID: 28287406
PubMed Central ID: 

Dulai P.S., Singh S., Patel J., Soni M., Prokop L.J., Younossi Z., Sebastiani G., Ekstedt M., Hagstrom H., Nasr P., Stal P., Wong V.W., Kechagias S., Hultcrantz R., Loomba R. (2017) Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 65(5):1557-1565. doi: 10.1002/hep.29085. Epub 2017 Mar 31.

PubMedID: 28130788
PubMed Central ID: 

Lin S.C., Heba E., Bettencourt R., Lin G.Y., Valasek M.A., Lunde O., Hamilton G., Sirlin C.B., Loomba R. (2017) Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging. Aliment Pharmacol Ther. 45(6):844-854. doi: 10.1111/apt.13951. Epub 2017 Jan 24.

PubMedID: 28116801
PubMed Central ID: 

Koyama Y., Brenner D.A. (2017) Liver inflammation and fibrosis. J Clin Invest. 127:55-64. doi: 10.1172/JCI88881.

PubMedID: 28045404
PubMed Central ID: 

Park C.C., Nguyen P., Hernandez C., Bettencourt R., Ramirez K., Fortney L., Hooker J., Sy E., Savides M.T., Alquiraish M.H., Valasek M.A., Rizo E., Richards L., Brenner D., Sirlin C.B., Loomba R. (2017) Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease. Gastroenterology. 152:598-607. doi: 10.1053/j.gastro.2016.10.026.

PubMedID: 27911262
PubMed Central ID: 

Koyama Y., Xu J., Liu X., Brenner D.A. (2016) New Developments on the Treatment of Liver Fibrosis. Dig Dis. 34:589-96. doi: 10.1159/000445269.

PubMedID: 27332862
PubMed Central ID: 

Wang P., Koyama Y., Liu X., Xu J., Ma H.Y., Liang S., Kim I.H., Brenner D.A., Kisseleva T. (2016) Promising Therapy Candidates for Liver Fibrosis. Front Physiol. 7:47. doi: 10.3389/fphys.2016.00047.

PubMedID: 26909046
PubMed Central ID: 

Liang S., Kisseleva T., Brenner D.A. (2017) The Role of NADPH Oxidases (NOXs) in Liver Fibrosis and the Activation of Myofibroblasts. Front Physiol. 7:17. doi: 10.3389/fphys.2016.00017. eCollection 2016.

PubMedID: 26869935
PubMed Central ID: 

Brenner, D. A., Paik, Y. H., Schnabl, B. (2015) Role of Gut Microbiota in Liver Disease. J Clin Gastroenterol. 49 Suppl 1:S25-7. doi: 10.1097/MCG.0000000000000391.

PubMedID: 26447960
PubMed Central ID: 

Lan, T., Kisseleva, T., Brenner, D.A. (2015) Deficiency of NOX1 or NOX4 Prevents Liver Inflammation and Fibrosis in Mice through Inhibition of Hepatic Stellate Cell Activation. PLoS One. 10(7):e0129743. doi: 10.1371/journal.pone.0129743.

PubMedID: 26222337
PubMed Central ID: 

Koyama, Y., Brenner, D. A. (2015) New therapies for hepatic fibrosis. Clin Res Hepatol Gastroenterol. 39 Suppl 1, S75-9. doi: 10.1016/j.clinre.2015.06.011.

PubMedID: 26206573
PubMed Central ID: 

Seki, E., Brenner, D. A. (2015) Recent advancement of molecular mechanisms of liver fibrosis. J Hepatobiliary Pancreat Sci. 22(7):512-8. doi: 10.1002/jhbp.245

PubMedID: 25869468
PubMed Central ID: 

Kim, I. H., Kisseleva, T., Brenner, D. A. (2015) Aging and liver disease. Curr Opin Gastroenterol. 31(3):184-91. doi: 10.1097/MOG.0000000000000176.

PubMedID: 25850346
PubMed Central ID: 

Fang, S., Suh, J. M., Reilly, S. M., Yu, E., Osborn, O., Lackey, D., Yoshihara, E., Perino, A., Jacinto, S., Lukasheva, Y., Atkins, A. R., Khvat, A., Schnabl, B., Yu, R. T., Brenner, D. A., Coulter, S., Liddle, C., Schoonjans, K., Olefsky, J. M., Saltiel, A. R., Downes, M., Evans, R. M. (2015) Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med. 21(2):159-65. doi: 10.1038/nm.3760.

PubMedID: 25559344
PubMed Central ID: 

Mazagova, M., Wang, L., Anfora, A. T., Wissmueller, M., Lesley, S. A., Miyamoto, Y., Eckmann, L., Dhungana, S., Pathmasiri, W., Sumner, S., Westwater, C., Brenner, D. A., Schnabl, B. (2015) Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. FASEB J. 29(3):1043-55. doi: 10.1096/fj.14-259515.

PubMedID: 25466902
PubMed Central ID: 

Lopez-Sanchez, I., Dunkel, Y., Roh, Y. S., Mittal, Y., De Minicis, S., Muranyi, A., Singh, S., Shanmugam, K., Aroonsakool, N., Murray, F., Ho, S. B., Seki, E., Brenner, D. A., Ghosh, P. (2014) GIV/Girdin is a central hub for profibrogenic signalling networks during liver fibrosis. Nat Commun. 5:4451. doi: 10.1038/ncomms5451.

PubMedID: 25043713
PubMed Central ID: 

Inokuchi-Shimizu, S., Park, E. J., Roh, Y. S., Yang, L., Zhang, B., Song, J., Liang, S., Pimienta, M., Taniguchi, K., Wu, X., Asahina, K., Lagakos, W., Mackey, M. R., Akira, S., Ellisman, M. H., Sears, D. D., Olefsky, J. M., Karin, M., Brenner, D. A., Seki, E. (2014) ETAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis. J Clin Invest. 124(8), 3566-78. doi: 10.1172/JCI74068.

PubMedID: 24983318
PubMed Central ID: 

Liu, C., Chen, X., Yang, L., Kisseleva, T., Brenner, D. A., Seki, E. (2014) Transcriptional Repression of the Transforming Growth Factor β (TGF-β) Pseudoreceptor BMP and Activin Membrane-bound Inhibitor (BAMBI) by Nuclear Factor κB (NF-κB) p50 Enhances TGF-β Signaling in Hepatic Stellate Cells. J Biol Chem. 289(10):7082-91. doi: 10.1074/jbc.M113.543769.

PubMedID: 24448807
PubMed Central ID: 

Schnabl, B., Brenner, D. A. (2014) Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 146(6):1513-24. doi: 10.1053/j.gastro.2014.01.020.

PubMedID: 24440671
PubMed Central ID: 

Paik, Y. H., Kim, J., Aoyama, T., De Minicis, S., Bataller, R., Brenner, D. A. (2014) Role of NADPH Oxidases in Liver Fibrosis. Antioxid Redox Signal. 20(17):2854-72. doi: 10.1089/ars.2013.5619.

PubMedID: 24040957
PubMed Central ID: 

Madsen, D. H., Leonard, D., Masedunskas, A., Moyer, A., Jürgensen, H. J., Peters, D. E., Amornphimoltham, P., Selvaraj, A., Yamada, S. S., Brenner, D. A., Burgdorf, S., Engelholm, L. H., Behrendt, N., Holmbeck, K., Weigert, R., Bugge, T. H. (2013) M2-like macrophages are responsible for collagen degradation through a mannose receptor-mediated pathway J Cell Biol. 202(6):951-66. doi: 10.1083/jcb.201301081.

PubMedID: 24019537
PubMed Central ID: 

Seki, E., Brenner, D. A., Karin, M. (2012) A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology. 143(2), 307-20. doi: 10.1053/j.gastro.2012.06.004.

PubMedID: 22705006
PubMed Central ID: 

Österreicher, C.H., Penz-Österreicher, M., Grivennikov, S. I., Guma, M., Koltsova, E. K., Datz, C., Sasik, R., Hardiman, G., Karin, M., Brenner, D. A., (2011) Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. Proc Natl Acad Sci USA. 108(1), 308-13. doi: 10.1073/pnas.1017547108.

PubMedID: 21173249

Main Contact Information


Project Leaders
  • Dr. David A. Brenner
    Dean, UCSD School of Medicine; Vice Chancellor for Health Sciences

  • Dr. Rohit Loomba
    Professor, Division of Gastroenterology, Department of Medicine, UCSD School of Medicine
Superfund Project Members
  • Tatiana Kisseleva, Researcher
  • Jacopo Baglieri, Post-Doctoral Scholar
  • Karin Diggle, Lab Manager

Contact

UCSD Superfund Research Center
University of California, San Diego
Pharmacology Department
9500 Gilman Drive, Mail Code 0722
La Jolla, CA 92093-0722